Sinergium Biotech is an Argentine biotechnology company headquartered in Buenos Aires, Argentina. Founded in 2009, the company initially focused on vaccine development and has subsequently expanded into neuroscience research, with particular emphasis on neuroimmunology approaches to neurodegenerative diseases including Alzheimer's disease[1].
The company's expansion into neurodegeneration reflects the growing burden of Alzheimer's disease in Latin America and the recognition that immunological approaches may offer promising therapeutic strategies. Sinergium leverages its expertise in antibody development and immunological research to target neuroinflammatory pathways implicated in neurodegenerative disease progression.
| Attribute | Details |
|---|---|
| Headquarters | Buenos Aires, Argentina |
| Founded | 2009 |
| Focus Areas | Vaccines, Biotechnology, Neuroscience |
| Employees | ~250 |
| Stage | Commercial stage with R&D |
Sinergium Biotech was established in Buenos Aires as a vaccine development company, capitalizing on Argentina's strong foundation in immunology research. The company developed and commercialized several vaccines for infectious diseases, establishing manufacturing capabilities and regulatory expertise.
In recent years, Sinergium diversified its pipeline to include oncology and, more recently, neuroscience programs. This expansion was motivated by the high prevalence of neurodegenerative diseases in Argentina and Latin America, with estimates suggesting over 500,000 people living with Alzheimer's disease in Argentina alone[2].
The company's neuroscience division was established in 2020, recruiting researchers with expertise in neuroimmunology and establishing collaborations with academic institutions in Argentina and internationally.
Sinergium's lead neurodegeneration program focuses on Alzheimer's disease, targeting neuroinflammatory pathways that contribute to disease progression. The company's approach involves:
Immunotherapy Approaches:
Target Pathways:
Sinergium has established research partnerships with Argentine academic institutions:
University of Buenos Aires (UBA):
Instituto de Neurociencias de Buenos Aires (INBA):
| Program | Target | Stage | Indication |
|---|---|---|---|
| SYN-001 | NLRP3 inflammasome | Preclinical | Alzheimer's disease |
| SYN-002 | Tau oligomers | Discovery | Alzheimer's disease |
| SYN-003 | Neuroinflammation | Discovery | Parkinson's disease |
Sinergium has developed capabilities in antibody discovery and engineering:
Hybridoma Technology:
Phage Display:
The company's core immunology expertise includes:
Sinergium operates manufacturing facilities in Buenos Aires meeting international standards:
The company has the capacity to manufacture biologics including monoclonal antibodies and vaccines, supporting both its commercial products and pipeline programs.
Sinergium has funded its growth through a combination of:
The company has established partnerships with:
Sinergium aims to become a leading Latin American biotechnology company in neuroscience, with:
Sinergium Biotech represents an emerging Argentine biotechnology company with expanding programs in neurodegenerative disease research. Leveraging its immunology expertise, the company is developing immunotherapy approaches targeting neuroinflammatory pathways in Alzheimer's disease. With manufacturing capabilities and academic partnerships, Sinergium is positioned to contribute to the Latin American neurodegeneration research ecosystem.
Garcia M, et al. Neuroimmunology approaches to Alzheimer's disease. 2023. ↩︎